Olsen 2004 — Alopecia areata investigational assessment guidelines (SALT definition, NAAF)
Citation
Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines — Part II. J Am Acad Dermatol. 2004 Sep;51(3):440–447. DOI: 10.1016/j.jaad.2003.09.032. PMID 15337988.
Study design and population
National Alopecia Areata Foundation (NAAF) expert-consensus guideline. Defines the Severity of Alopecia Tool (SALT) — a continuous 0–100 score derived from four weighted scalp quadrants (13 %, 13 %, 24 %, 40 %–50 %). Companion to Part I.
Reported outcomes
- SALT-II (Olsen 2016, JAAD, DOI 10.1016/j.jaad.2016.08.042) adds finer resolution increments
- SALT ≤ 20 and SALT-50 / 75 / 90 response thresholds subsequently adopted in regulatory trials (baricitinib, ritlecitinib, deuruxolitinib)
- Consensus-derived instrument; no empirical reliability statistics in this publication
Surrogate-to-outcome linkage
Consensus genesis of SALT as the regulator-accepted severity surrogate for alopecia areata. Downstream FDA / EMA approvals for JAK-inhibitor therapy use SALT response as the primary efficacy definition, anchoring it as a patient-relevant outcome proxy in the pivotal-trial literature.
CRIT1–7 appraisal
| Criterion | Score | Justification |
|---|---|---|
| CRIT1 Relevance | 3 | Foundational — defines the SALT surrogate used in all subsequent AA trials. |
| CRIT2 Methodology | n/a | Consensus guideline (expert panel). |
| CRIT3 Reporting | 2 | Instrument definition clear; no empirical psychometrics in this paper. |
| CRIT4 Applicability | 3 | Used verbatim in FDA / EMA-approved pivotal trials. |
| CRIT5 Evidence weight | 1 | Expert consensus document. |
| CRIT6 Risk of bias | 2 | Consensus without underlying reliability data at time of publication. |
| CRIT7 Contribution | 3 | Essential — without SALT definition, the baricitinib / ritlecitinib approvals have no surrogate. |
Aggregate: strong (foundational).
Limitations and notes
No empirical reliability statistics in the original paper; reliability data come from subsequent validations and from the regulatory approval dossiers.
Strength as anchor
Strong as a foundational definition reference. Always paired with King 2022 (baricitinib BRAVE-AA) for the empirical response-to-therapy linkage.